<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>药融圈 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-06T11:41:34+08:00</updated>
  <subtitle>药融圈PHARNEX汇聚数万医药大咖，得到数千家医药创业者鼎力支持，开展日常专题讲座。致力于成为“专业、前沿、权威、严谨”的医药行业资讯平台，以及项目、技术、工厂、融资、股权投资等资源整合平台。欢迎您关注药融圈，共同碰撞“药”的火花!</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>零度下的思考，差异化的机遇—未来10年医药业7大变局</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/k35OFcrg5ZUEDICe_UIFGA</id>
    <link href="https://mp.weixin.qq.com/s/k35OFcrg5ZUEDICe_UIFGA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>绿叶制药：博安生物完成6.82亿元战略融资，加速生物药全球布局</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/wcSTTg4pOVNqAN9y_8jgaw</id>
    <link href="https://mp.weixin.qq.com/s/wcSTTg4pOVNqAN9y_8jgaw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Angelini Pharma以9.6亿美元收购Arvelle，获得癫痫新药欧洲权益</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/YBdfMI-UJ76zccNRYOhTkw</id>
    <link href="https://mp.weixin.qq.com/s/YBdfMI-UJ76zccNRYOhTkw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞PD-1或成百亿大品种，PD-(L)1领域已成红海！</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/lcxVhkMdFYV3SsHv4C1TwA</id>
    <link href="https://mp.weixin.qq.com/s/lcxVhkMdFYV3SsHv4C1TwA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Paratek获得康桥资本旗下R-Bridge无追索权贷款投资6000万美元</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/wLbzLniTQWIuHWGsFohH_Q</id>
    <link href="https://mp.weixin.qq.com/s/wLbzLniTQWIuHWGsFohH_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE发布《儿童用药（化学药品）药学开发指导原则（试行）》</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/hk5KUYQNqTwsUfEwnFGE1A</id>
    <link href="https://mp.weixin.qq.com/s/hk5KUYQNqTwsUfEwnFGE1A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>盘点：2020年全球上市药物汇总</title>
    <updated>2021-01-05T22:51:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-05:/s/_SAv3sm8nKy1L2ut2q86Xg</id>
    <link href="https://mp.weixin.qq.com/s/_SAv3sm8nKy1L2ut2q86Xg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>谁在成为中国的Celgene?</title>
    <updated>2021-01-04T16:29:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/sUPuib-uFD_e6Zo3TPFlKA</id>
    <link href="https://mp.weixin.qq.com/s/sUPuib-uFD_e6Zo3TPFlKA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>改良型新药临床怎么做？CDE发布《化学药品改良型新药临床试验技术指导原则》，即日施行！</title>
    <updated>2021-01-04T16:29:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/6O2HyWURv1teQ238tUX4Yw</id>
    <link href="https://mp.weixin.qq.com/s/6O2HyWURv1teQ238tUX4Yw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>一致性评价周总结（12.22-12.28）：大批品种迎过评,多款药品集齐三家及以上!</title>
    <updated>2021-01-04T16:29:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/z_AbRbSwZpoM4dhWWlh4hA</id>
    <link href="https://mp.weixin.qq.com/s/z_AbRbSwZpoM4dhWWlh4hA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>基于共刺激分子4-1BB的双特异性抗体</title>
    <updated>2021-01-04T16:29:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/NW90YfbKmN5VvmAsMgF0TA</id>
    <link href="https://mp.weixin.qq.com/s/NW90YfbKmN5VvmAsMgF0TA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>难逃此劫：百时美施贵宝（BMS）宣布撤出O药小细胞肺癌美国市场</title>
    <updated>2021-01-04T16:29:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/waUcmJhOhUamsWTNSu9gAA</id>
    <link href="https://mp.weixin.qq.com/s/waUcmJhOhUamsWTNSu9gAA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>靶点药讯42|纵览全球药物靶点动态</title>
    <updated>2021-01-04T16:29:32+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-04:/s/1Ohzm33pPFrW7c61uImp9w</id>
    <link href="https://mp.weixin.qq.com/s/1Ohzm33pPFrW7c61uImp9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>益方KRAS已美国临床，国内上市辅导中</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/nwAjwz0n1t8vPcxRJcU8vA</id>
    <link href="https://mp.weixin.qq.com/s/nwAjwz0n1t8vPcxRJcU8vA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>JMC：FBDD药物发现技术盘点</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/BZLtsve2590P-YhWqrGddA</id>
    <link href="https://mp.weixin.qq.com/s/BZLtsve2590P-YhWqrGddA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>从CDE承办-知晓药研动向，盘点2020年中国药品审评</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/VnuUVtsKh0m-pJfLIVxGfA</id>
    <link href="https://mp.weixin.qq.com/s/VnuUVtsKh0m-pJfLIVxGfA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CDE公告：《药品审评审批信息公开管理办法》，25条，2021年6月1日起施行</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/XAme7Erxuz7fdCauyhHnCQ</id>
    <link href="https://mp.weixin.qq.com/s/XAme7Erxuz7fdCauyhHnCQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>简评靶向GPCR的临床在研抗体</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/njKT75tHZ9TH4yAkLYyeFQ</id>
    <link href="https://mp.weixin.qq.com/s/njKT75tHZ9TH4yAkLYyeFQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>神经精神疾病领域的创新靶标</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/8MohPxa6tl2OeFoWHJvF9w</id>
    <link href="https://mp.weixin.qq.com/s/8MohPxa6tl2OeFoWHJvF9w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>基于PD-1/L1的双特异抗体突破在何方？</title>
    <updated>2021-01-03T20:24:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-03:/s/9TpfL6vgwiDxElFx1aweTA</id>
    <link href="https://mp.weixin.qq.com/s/9TpfL6vgwiDxElFx1aweTA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>